La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
GlycoMimetics Gestion
Gestion contrôle des critères 2/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Harout Semerjian
Directeur général
US$2.4m
Rémunération totale
| Pourcentage du salaire du PDG | 26.7% |
| Durée du mandat du directeur général | 3yrs |
| Propriété du PDG | 0.04% |
| Durée moyenne d'occupation des postes de direction | 3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.9yrs |
Mises à jour récentes de la gestion
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | US$2m | US$638k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$38m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$1m | US$614k | -US$47m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$3m | US$244k | -US$63m |
Rémunération vs marché: La rémunération totale de Harout ($USD 2.39M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).
Rémunération et revenus: La rémunération de Harout a augmenté alors que l'entreprise n'est pas rentable.
PDG
Harout Semerjian (54 yo)
3yrs
Titularisation
US$2,389,418
Compensation
Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.39m | 0.039% $ 4.6k | |
| Co-Founder & Director | 21.6yrs | US$96.00k | 0.98% $ 117.5k | |
| Senior VP & CFO | 12.6yrs | US$1.30m | 0.096% $ 11.5k | |
| Senior VP & Chief Medical Officer | 1.9yrs | US$1.15m | 1.06% $ 125.9k | |
| Vice President of Accounting | 5.6yrs | pas de données | pas de données | |
| General Counsel & Company Secretary | 5.3yrs | pas de données | pas de données | |
| Senior VP & Chief Commercial Officer | 2.5yrs | pas de données | 0.22% $ 25.7k | |
| Senior VP & Chief Business Officer | 1.5yrs | pas de données | 0.25% $ 29.8k | |
| Senior Vice President of Technical Operations | less than a year | pas de données | pas de données |
3.0yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de GLYC est considérée comme expérimentée (ancienneté moyenne 3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.39m | 0.039% $ 4.6k | |
| Co-Founder & Director | 21.6yrs | US$96.00k | 0.98% $ 117.5k | |
| Independent Director | 8.4yrs | US$118.50k | 0.15% $ 18.2k | |
| Independent Chairman of the Board | 10.4yrs | US$138.00k | 0.038% $ 4.6k | |
| Independent Director | 7.4yrs | US$100.50k | 0.057% $ 6.8k | |
| Independent Director | 5.8yrs | US$111.00k | 0.0081% $ 971.1 | |
| Independent Director | 7.2yrs | US$105.00k | 0.091% $ 10.8k | |
| Independent Director | 10.1yrs | US$111.00k | pas de données |
7.9yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de GLYC sont considérés comme expérimentés (ancienneté moyenne 7.9 ans).